Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

87.59
5,119,705

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock

by Zacks Equity Research

AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

by Zacks Equity Research

IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.

Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the most recent trading session, Boston Scientific (BSX) closed at $81.79, indicating a +1.39% shift from the previous trading day.

Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131

by Zacks Equity Research

CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.

Should You Consider Retaining Bruker Stock in Your Portfolio Now?

by Zacks Equity Research

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up

by Zacks Equity Research

CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.

Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure

by Zacks Equity Research

In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.

New Launches Support Tandem Diabetes Stock Despite Macro Concerns

by Zacks Equity Research

The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.

COO Stock Gains on Q3 Earnings & Revenue Beat, Margins Up

by Zacks Equity Research

Cooper Companies' solid segmental results led to an encouraging fiscal third-quarter performance, driving up share prices in after-hours trading.

Neogen (NEOG) Down 1.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark

by Zacks Equity Research

BSX achieves CE Mark approval for the ACURATE Prime Aortic Valve System, its latest TAVR technology.

ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx

by Zacks Equity Research

Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

by Zacks Equity Research

NEOG faces intense competition, which could affect the marketability and profitability of its products.

PDCO Stock Falls on Q1 Earnings & Sales Miss, Gross Margin Up Y/Y

by Zacks Equity Research

Patterson Companies' first-quarter fiscal 2025 results reflect the negative impact of a cyberattack on its vendor, Change Healthcare.

ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition

by Zacks Equity Research

Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.

Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?

by Zacks Equity Research

GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.

Abbott's Core Businesses Thrive Despite Macroeconomic Issues

by Zacks Equity Research

ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.

Verano Expands U.S. Cannabis Footprint With New Buyouts

by Zacks Equity Research

This deal helps VRNOF foray into the Virginia market ahead of the Adult Use Program launch and will deepen the company's footprint in Arizona cannabis market.

Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes

by Zacks Equity Research

PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.

Quest Diagnostics Expands in North America With New Acquisition

by Zacks Equity Research

DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.

Reasons to Retain QIAGEN Stock in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.

MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition

by Zacks Equity Research

McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.

HAE vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

HAE vs. BSX: Which Stock Is the Better Value Option?

Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio

by Zacks Equity Research

Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.

Reasons to Retain ICON (ICLR) Stock in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.